As KDM3B has been implicated in taxane-platin-resistant small-cell lung cancer, acute lymphoblastic leukemia, and hepatocellular carcinoma, P3FI-90 emerges as a lead compound for further development using structure-activity relationship (SAR) to identify clinical grade KDM3B inhibitors against multiple cancers36–38. Here, KDM3B is linked to small cell lung carcinoma.